Loading...
Please wait, while we are loading the content...
Similar Documents
The clinical profile of benralizumab in the management of severe eosinophilic asthma
| Content Provider | SAGE Publishing |
|---|---|
| Author | Menzella, Francesco Lusuardi, Mirco Galeone, Carla Facciolongo, Nicola Zucchi, Luigi |
| Copyright Year | 2016 |
| Abstract | Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes makes correct patient selection increasingly complex and important. In this article, we discuss the features of benralizumab compared with other anti-interleukin-5 biologics and omalizumab, the identification of appropriate patients, the safety profile and future developments. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/1753465816667659?download=true |
| Starting Page | 534 |
| Ending Page | 548 |
| Page Count | 15 |
| ISSN | 17534666 |
| Issue Number | 6 |
| Volume Number | 10 |
| Journal | Therapeutic Advances in Respiratory Disease (TAR) |
| e-ISSN | 17534666 |
| DOI | 10.1177/1753465816667659 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2016-09-09 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s), 2016 |
| Subject Keyword | severe asthma eosinophils interleukin 5 cytokines biomarkers benralizumab anti-interleukin-5 monoclonal antibodies |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pulmonary and Respiratory Medicine Pharmacology (medical) |
